Innovative vaccines for a healthier world

We want to transform healthcare by developing novel vaccines that are life-saving and improving quality of life around the world.

Interview with CEO Bent Frandsen

Explore ExpreS2ion Biotechnologies, an innovator within biotechnology.
In a detailed interview, CEO Bent Frandsen outlines our progress in developing innovative vaccines for a healthier world.
Uncover the substantial impact of our pioneering work and the compelling reasons to invest.
Engage with us as we lead in transformative solutions through the advanced capabilities of ExpreS2ion Biotechnologies.
 

Next Event

  • Thu
    16
    May
    2024

    Presentation of 2024 first quarter results

    10:00H.C. Andersen Capital Webinar

    Join ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander as they provides insights into the 2023 fourth quarter and full-year results. Visit the H.C. Andersen Capital Events website for further details and registration information.

Latest News

ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS

Hørsholm, Denmark, 23 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announced that it has been notified by the Board of Directors of its associated company, AdaptVac ApS, of the resolution to pay a dividend of DKK 42.5 million (SEK 66.1 million) to its owners. As a result of ExpreS2ion…

Read more

ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the Board of Directors of ExpreS2ion has resolved to postpone the Company's annual general meeting and consequently also the publication of the annual report for 2023 due to administrative and practical reasons.

Read more

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate

Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate.

Read more